For these reasons, TGF-β1 could be a potential target in therapeutic strategies, also taking into account that although HCC is one of the most lethal cancers [53], there are very few therapeutic options at the advanced stage. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.